We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. On December 15, 2025, UBS reaffirmed its Neutral (Hold) rating on NVO with an unchanged price target of DKK 295, ...
So far five companies have agreed to the terms. They are Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk and EMD Serono, which ...
The investment narrative surrounding Novo Nordisk is undergoing a significant shift. After years of soaring expectations fueled by its obesity and diabetes t ...
The White House is set to announce drug pricing deals with pharmaceutical giants Novartis and Roche Holding as soon as Friday ...
Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...
By Mike Dolan Dec 16 - What matters in U.S. and global markets today By Mike Dolan, Editor-At-Large, Finance and Markets The ...
A federal judicial panel ordered that lawsuits alleging vision loss from Novo Nordisk’s (NVO) and Eli Lilly’s (LLY) weight-loss drugs be ...
Brazilian petrochemical producer Braskem on Monday said Novonor has signed an agreement that would ultimately lead to the ...
For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...
A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...
The U.S. Food and Drug Administration said on Monday it has granted a national priority voucher to Johnson & Johnson's blood ...
Health and Me on MSN
Ozempic launches in India at Rs 2,200 for starter dose: All you need to know
Novo Nordisk has launched its popular diabetes drug Ozempic in India, with the weekly 0.25 mg starter dose priced at ₹2,200.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback